Abstract
Purpose
To identify independent factors that may predict vesicoureteral reflux (VUR) resolution after endoscopic treatment using dextranomer/hyaluronic acid copolymer (Deflux®) in children free of anatomical anomalies.
Materials and methods
A retrospective study was conducted in our pediatric referral center from 1998 to 2011 on children with primary VUR who underwent endoscopic injection of Deflux® with or without concomitant autologous blood injection (called HABIT or HIT, respectively). Children with secondary VUR or incomplete records were excluded from the study. Potential factors were divided into three categories including preoperative, intraoperative and postoperative. Success was defined as no sign of VUR on postoperative voiding cystourethrogram. Univariate and multivariate logistic regression models were constructed to identify independent factors that may predict success. Odds ratio (OR) and 95 % confidence interval (95 % CI) for prediction of success were estimated for each factor.
Results
From 485 children received Deflux® injection, a total of 372 with a mean age of 3.10 years (ranged from 6 months to 12 years) were included in the study and endoscopic management was successful in 322 (86.6 %) of them. Of the patients, 185 (49.7 %) underwent HIT and 187 (50.3 %) underwent HABIT technique. On univariate analysis, VUR grade from preoperative category (OR = 4.79, 95 % CI = 2.22–10.30, p = 0.000), operation technique (OR = 0.33, 95 % CI = 0.17–0.64, p = 0.001) and presence of mound on postoperative sonography (OR = 0.06, 95 % CI = 0.02–0.16, p = 0.000) were associated with success. On multivariate analysis, preoperative VUR grade (OR = 4.85, 95 % CI = 2.49–8.96, p = 0.000) and identification of mound on postoperative sonography (OR = 0.07, 95 % CI = 0.01–0.18, p = 0.000) remained as independent success predictors.
Conclusion
Based on this study, successful VUR correction after the endoscopic injection of Deflux® can be predicted with respect to preoperative VUR grade and presence of mound after operation.
Similar content being viewed by others
References
Jacobson SH, Hansson S, Jakobsson B (1999) Vesico-ureteric reflux: occurrence and long-term risks. Acta Paediatr Suppl 88(431):22–30
Peters CA, Skoog SJ, Arant BS Jr, Copp HL, Elder JS, Hudson RG, Khoury AE, Lorenzo AJ, Pohl HG, Shapiro E, Snodgrass WT, Diaz M (2010) Summary of the AUA guideline on management of primary vesicoureteral reflux in children. J Urol 184(3):1134–1144. doi:10.1016/j.juro.2010.05.065
Diamond DA, Mattoo TK (2012) Endoscopic treatment of primary vesicoureteral reflux. N Engl J Med 366(13):1218–1226. doi:10.1056/NEJMct1108922
Elder JS, Diaz M, Caldamone AA, Cendron M, Greenfield S, Hurwitz R, Kirsch A, Koyle MA, Pope J, Shapiro E (2006) Endoscopic therapy for vesicoureteral reflux: a meta-analysis. I. Reflux resolution and urinary tract infection. J Urol 175(2):716–722. doi:10.1016/S0022-5347(05)00210-7
Kajbafzadeh AM, Tourchi A (2012) Usefulness of concomitant autologous blood and dextranomer/hyaluronic acid copolymer injection to correct vesicoureteral reflux. J Urol. doi:10.1016/j.juro.2012.04.119
Routh JC, Reinberg Y (2010) Predicting success in the endoscopic management of pediatric vesicoureteral reflux. Urology 76(1):195–198. doi:10.1016/j.urology.2009.09.017
Lebowitz RL, Olbing H, Parkkulainen KV, Smellie JM, Tamminen-Mobius TE (1985) International system of radiographic grading of vesicoureteric reflux. International Reflux Study in children. Pediatr Radiol 15(2):105–109
O’Donnell B, Puri P (1984) Treatment of vesicoureteric reflux by endoscopic injection of Teflon. Br Med J (Clin Res Ed) 289(6436):7–9
Chertin B, Kocherov S (2010) Long-term results of endoscopic treatment of vesicoureteric reflux with different tissue-augmenting substances. J Pediatr Urol 6(3):251–256. doi:10.1016/j.jpurol.2009.10.011
Molitierno JA, Scherz HC, Kirsch AJ (2008) Endoscopic treatment of vesicoureteral reflux using dextranomer hyaluronic acid copolymer. J Pediatr Urol 4(3):221–228. doi:10.1016/j.jpurol.2007.11.015
Kalisvaart JF, Scherz HC, Cuda S, Kaye JD, Kirsch AJ (2011) Intermediate to long-term follow-up indicates low risk of recurrence after Double HIT endoscopic treatment for primary vesico-ureteral reflux. J Pediatr Urol. doi:10.1016/j.jpurol.2011.07.006
Stenberg AM, Sundin A, Larsson BS, Lackgren G, Stenberg A (1997) Lack of distant migration after injection of a 125 iodine labeled dextranomer based implant into the rabbit bladder. J Urol 158(5):1937–1941
Kirsch A, Hensle T, Scherz H, Koyle M (2006) Injection therapy: advancing the treatment of vesicoureteral reflux. J Pediatr Urol 2(6):539–544. doi:10.1016/j.jpurol.2005.12.004
Kobelt G, Canning DA, Hensle TW, Lackgren G (2003) The cost-effectiveness of endoscopic injection of dextranomer/hyaluronic acid copolymer for vesicoureteral reflux. J Urol 169(4):1480–1484; discussion 1484–1485. doi:10.1097/01.ju.0000056638.75652.54S0022-5347(05)63798-6
Tekgul S, Riedmiller H, Hoebeke P, Kocvara R, Nijman RJ, Radmayr C, Stein R, Dogan HS (2012) EAU guidelines on vesicoureteral reflux in children. Eur Urol. doi:10.1016/j.eururo.2012.05.059
Lackgren G, Stenberg A (2009) Endoscopic treatment of vesicoureteral reflux: current practice and the need for multifactorial assessment. Ther Adv Urol 1(3):131–141. doi:10.1177/1756287209342731
Dave S, Lorenzo AJ, Khoury AE, Braga LH, Skeldon SJ, Suoub M, Farhat W, Pippi Salle JL, Bagli DJ (2008) Learning from the learning curve: factors associated with successful endoscopic correction of vesicoureteral reflux using dextranomer/hyaluronic acid copolymer. J Urol 180(4 Suppl):1594–1599; discussion 1599–1600. doi:10.1016/j.juro.2008.03.084
Lorenzo AJ, Pippi Salle JL, Barroso U, Cook A, Grober E, Wallis MC, Bagli DJ, Khoury AE (2006) What are the most powerful determinants of endoscopic vesicoureteral reflux correction? Multivariate analysis of a single institution experience during 6 years. J Urol 176(4 Pt 2):1851–1855. doi:10.1016/S0022-5347(06)00599-4
Puri P, Pirker M, Mohanan N, Dawrant M, Dass L, Colhoun E (2006) Subureteral dextranomer/hyaluronic acid injection as first line treatment in the management of high grade vesicoureteral reflux. J Urol 176 (4 Pt 2):1856–1859; discussion 1859–1860. doi:10.1016/j.juro.2006.03.124
Routh JC, Reinberg Y, Ashley RA, Inman BA, Wolpert JJ, Vandersteen DR, Husmann DA, Kramer SA (2007) Multivariate comparison of the efficacy of intraureteral versus subtrigonal techniques of dextranomer/hyaluronic acid injection. J Urol 178(4 Pt 2):1702–1705; discussion 1705–1706. doi:10.1016/j.juro.2007.03.174
Yucel S, Gupta A, Snodgrass W (2007) Multivariate analysis of factors predicting success with dextranomer/hyaluronic acid injection for vesicoureteral reflux. J Urol 177(4):1505–1509. doi:10.1016/j.juro.2006.11.077
Kirsch AJ, Perez-Brayfield MR, Scherz HC (2003) Minimally invasive treatment of vesicoureteral reflux with endoscopic injection of dextranomer/hyaluronic acid copolymer: the Children’s Hospitals of Atlanta experience. J Urol 170(1):211–215. doi:10.1097/01.ju.0000072523.43060.a0S0022-5347(05)63483-0
Lavelle MT, Conlin MJ, Skoog SJ (2005) Subureteral injection of Deflux for correction of reflux: analysis of factors predicting success. Urology 65(3):564–567. doi:10.1016/j.urology.2004.09.068
Serrano-Durba A, Serrano AJ, Magdalena JR, Martin JD, Soria E, Dominguez C, Estornell F, Garcia-Ibarra F (2004) The use of neural networks for predicting the result of endoscopic treatment for vesico-ureteric reflux. BJU Int 94(1):120–122. doi:10.1111/j.1464-410X.2004.04912.xBJU4912
Lackgren G, Skoldenberg E, Stenberg A (2007) Endoscopic treatment with stabilized nonanimal hyaluronic acid/dextranomer gel is effective in vesicoureteral reflux associated with bladder dysfunction. J Urol 177(3):1124–1128; discussion 1128–1129. doi:10.1016/j.juro.2006.10.094
Molitierno JA Jr, Scherz HC, Kirsch AJ (2008) Endoscopic injection of dextranomer hyaluronic acid copolymer for the treatment of vesicoureteral reflux in duplex ureters. J Pediatr Urol 4(5):372–376. doi:10.1016/j.jpurol.2008.01.216
Cerwinka WH, Scherz HC, Kirsch AJ (2007) Endoscopic treatment of vesicoureteral reflux associated with paraureteral diverticula in children. J Urol 178(4 Pt 1):1469–1473. doi:10.1016/j.juro.2007.05.168
Bar-Yosef Y, Castellan M, Joshi D, Labbie A, Gosalbez R (2011) Salvage dextranomer-hyaluronic acid copolymer for persistent reflux after ureteral reimplantation: early success rates. J Urol 185(6 Suppl):2531–2534. doi:10.1016/j.juro.2011.01.014
Ben-Meir D, Morgenstern S, Sivan B, Efrat R, Livne PM (2012) Histology proved malpositioning of dextranomer/hyaluronic Acid in submucosal ureter in patients after failed endoscopic treatment of vesicoureteral reflux. J Urol 188(1):258–261. doi:10.1016/j.juro.2012.03.019
Ellsworth PI, Yates JK, Caldamone AA (2011) Presence of dextranomer-hyaluronic acid (DxHA) mound on postoperative ultrasound does not predict resolution of vesicoureteral reflux. J Pediatr Urol 7(4):438–440. doi:10.1016/j.jpurol.2010.05.008
Conflict of interest
No conflict of interest exists in relation to the submitted manuscript, and there was no source of extra-institutional commercial funding or funding received from National Institutes of Health (NIH), Wellcome Trust, Howard Hughes Medical Institute (HHMI) and others.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kajbafzadeh, AM., Tourchi, A. & Aryan, Z. Factors that impact the outcome of endoscopic correction of vesicoureteral reflux: a multivariate analysis. Int Urol Nephrol 45, 1–9 (2013). https://doi.org/10.1007/s11255-012-0327-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11255-012-0327-5